In order to deeply implement the "Opinions of the Central Committee of the Communist Party of China and the State Council on Supporting the Construction of Shenzhen as a Pilot Demonstration Zone for Socialism with Chinese Characteristics" and plan to promote high-quality innovative development of the biopharmaceutical industry in Shenzhen and Pingshan at a higher starting point and level, the "2019 Shenzhen International Biopharmaceutical Industry Innovation and Development Summit" was held at the Yanzihu International Convention and Exhibition Center in Pingshan District, Shenzhen from September 11 to September 12. Jiang Yuyang, Deputy Director of the Standing Committee of the Shenzhen Municipal People's Congress and Chairman of the Shenzhen Science and Technology Association, Wu You, Deputy Secretary General of the Shenzhen Municipal People's Government, Qiu Xuan, Secretary and Deputy Director of the Party Group of the Shenzhen Science and Technology Innovation Committee, Tao Yongxin, Secretary of the Shenzhen Pingshan District Committee, Li Yong, District Mayor of the Shenzhen Pingshan District People's Government, Sun Xinhua, Director of the Shenzhen Pingshan District People's Congress Standing Committee, and other leaders attended the relevant activities of the meeting. More than 100 academicians, scientists, experts and scholars from the field of biopharmaceuticals both domestically and internationally, as well as nearly a thousand experts and scholars from government regulatory agencies, Fortune 500 companies, international innovation research project teams, and international venture capital institutions, senior executives, and technical elites, attended the summit.

In this biopharmaceutical grand event with the theme of "focusing on the new biological economy and seeking innovation in the Greater Bay Area", the participants conducted in-depth discussions on how to give play to the "dual zone" driving effect of the Guangdong Hong Kong Macao Greater Bay Area and the pilot demonstration area, and accelerate the building of a global biobased economy pilot area, so as to give full play to the "golden signboard" of the national biological industry base in Heping Mountain Area, Shenzhen, A construction model and implementation path have been proposed to build a world-class biopharmaceutical industry highland in the Guangdong Hong Kong Macao Greater Bay Area with the posture of "main battlefield".

——More than 100 biological industry celebrities gathered, forming a strong consensus to build Pingshan into a global biobased economy pilot area

This summit attracted more than 100 industry leaders and renowned experts from the global biopharmaceutical field, including Nobel laureate George Fitzgerald Smooth in 2006, Jean Pierre CAZENAVE, Sun Dong, Han Zhongchao, Lu Yulin, Sun Yongkui, Zhang Lihe, and Zhang Dongxiao, as well as 8 domestic and foreign academicians, as well as 5 well-known university presidents. The summit also invited Song Ruilin, President of the China Association for the Promotion of Pharmaceutical Innovation, Zhu Xun, Chairman of the Tongyi New Drug Talent Club, Chen Jinyu, Executive Director of the Hong Kong Biomedical Innovation Association, Liao Bing, President of the Guangdong Academy of Sciences, Rui Guozhong, Director of the China Medical Science and Technology Achievement Transformation Center, Chen Zhijian, Vice President of Global R&D at AstraZeneca, Sun Zhengjie, Vice President of Strategy and Transformation at Merck China, and Yang Zhi, Co founder of the National Research Baiao Fund A large number of heavyweight guests attended, including Li Chuyuan, Chairman of Guangzhou Pharmaceutical Group, Lu Xianping, President and Chief Scientific Officer of Shenzhen Microchip Biotechnology Co., Ltd., and Yuan Qing, General Manager of Wanle Pharmaceutical.

At the meeting, George Fitzgerald Smoot, the 2006 Nobel Prize winner and professor of the University of California, Berkeley, USA, and Li Qing, former director of the Medical and Health Science and Technology Development Research Center of the National Health Commission and vice president of Peking Union Medical College of the Chinese Academy of Medical Sciences, respectively delivered keynote speeches entitled "Exploring the Unlimited Potential of Life Science and Artificial Intelligence" and "Construction of Medical Science and Technology Innovation System", Vice President of the Hong Kong Polytechnic University, Wei Bingjiang, Honorary President of Hong Kong Baptist University, Academician Chen Xinzi, and Dean of the School of Life and Health Sciences at the Chinese University of Hong Kong (Shenzhen), Ye Dequan, held a President (Academician) Forum under the theme of "Development of Life Sciences and Innovative Technology in China". Academicians from home and abroad, such as Zhang Lihe, Sun Yongkui, Zhang Dongxiao, Han Zhongchao, and Sun Dong, held high-end dialogues on the innovative development of biopharmaceuticals, Full on-site communication, warm atmosphere, and continuous applause. The attending guests focused on the cutting-edge fields of global biopharmaceutical technology innovation and the development of the biopharmaceutical industry, closely grasping the major opportunities for the construction of the Guangdong Hong Kong Macao Greater Bay Area and the leading demonstration zone, and put forward many valuable insights. In particular, he fully affirmed the great achievements of Shenzhen City and Pingshan District in the development of biomedicine, and said that under the background of the era when Shenzhen is building a leading demonstration zone of socialism with Chinese characteristics, Pingshan will certainly make great achievements in the field of biomedicine, and must seize the momentum to build a global biobased economy pilot zone, providing strong support for Shenzhen to accelerate the construction of a global highland of biomedicine industry.

During the summit, Tao Yongxin, Secretary of the Pingshan District Committee, stated that "top experts from the biopharmaceutical industry from all over the world have gathered in Pingshan to jointly plan and study how the Pingshan biopharmaceutical industry can create an innovative ecosystem and participate in international competition under the" dual zone "driving effect of the Guangdong Hong Kong Macao Greater Bay Area and the leading demonstration area. This will promote the high-quality development of the biopharmaceutical industry in Shenzhen and even the Guangdong Hong Kong Macao Greater Bay Area, It is of great significance to embark on a new path of internationalization, marketization, specialization, and high-end development with distinct characteristics.

——7 industry experts have become think tanks, 3 important agreements have been signed and reached, and the convergence of high-end elements in the biopharmaceutical industry has accelerated

At the summit, Hu Dingxu, member of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference and former chairman of the Hong Kong Medical Administration, Lu Yulin, president of the Hong Kong Biomedical Innovation Association and honorary academician of the Hong Kong University of Science and Technology, Sun Yongkui, academician of the National Academy of Engineering, Zhu Xun, chairman of the Freehand New Drug Talent Club, expert and chairman of the National New Drug Evaluation Committee, Lu Xianping, president and chief scientist of Shenzhen Microcore Biotechnology Co., Ltd, Seven industry elites, including Liu Yaonan, Chairman of Armored Yao Biomedical Technology (Management) Co., Ltd. and Athenex CEO, and Zhang Dan, Executive Chairman of Fangen Pharmaceutical Development Co., Ltd., have been hired as advisors to the Pingshan District Committee and Government. Along with Tian Yuan, Chairman of the Yabuli Forum, and Song Ruilin, Chairman of the China Association for the Promotion of Pharmaceutical Innovation, and two other advisors to the Pingshan District Committee and Government, a strong formation of nine advisors has been formed in Pingshan District, We will continue to contribute professional opinions to the construction of a modern and international biopharmaceutical innovation ecosystem in Pingshan.

At the summit, the People's Government of Pingshan District and Sanofi Pasteur Biological Products Co., Ltd. collaborated to establish a Memorandum of Understanding for the Vaccine Innovation Center, and signed a framework agreement for the construction of an integrated clinical research service platform with Hangzhou Taige Pharmaceutical Technology Co., Ltd., as well as a strategic cooperation framework agreement with Shantou University, And released the "Pingshan Biopharmaceutical Industry Innovation and Development Blue Book (2019)" jointly developed by Pingshan District and Huoshi Creation. This report interprets the development trend of regional industries through data analysis, analyzes the development situation of Pingshan's biopharmaceutical industry, insight into the essence of Pingshan's industrial development, presents a three-dimensional panoramic view of Pingshan's biopharmaceutical industry development, and points out the development trend and future path.

——“1+1+3+7”The mode is exciting and diverse, comprehensively building a high-end platform for cooperation in the biotechnology industry

This summit adopts the "1+1+3+7" model for the first time (i.e. one closed door meeting of experts, one main forum, three thematic discussions, and seven sub forums), focusing on topics in the forefront of global biopharmaceutical technology innovation and the development of the biopharmaceutical industry through a "facing the forefront, focusing on hotspots, and looking forward to the future" approach for in-depth exchanges. In particular, experts and scholars warmly exchanged key issues in the biopharmaceutical industry during activities such as the Bay Area Seminar on the Transformation of Research and Development in the Biopharmaceutical Industry, the Forum on Maternal and Child Health and Life Health Industry, the Opportunity Seminar on Innovative Drug Research and Development in the Greater Bay Area of Guangdong Hong Kong Macao, the Biopharmaceutical and Medical Device Project Roadshow, the Clinical Research Branch of Innovative Drugs for Liver Diseases, the Hong Kong Pharmaceutical Innovation Association Forum, and the Precision Medical Industry University Research Innovation Forum, And from the perspective of building innovative systems and models throughout the entire process of research and development, investment, production, manufacturing, experimentation, clinical practice, etc., in-depth exploration was conducted on the latest trends in related technologies and industries. Project roadshows and capital docking activities were also held simultaneously on the site. Changzhou Bida, Serena, Haggard and many other enterprises and projects participated in the roadshow, and project docking was carried out with financial capital such as Yuanming Capital, Bangqin Capital, Yabuli Investment and Innovation, and a full chain platform for scientific and technological industry development and cooperation covering academic discussions, technology research and development, and transformation of scientific and technological achievements into project financing was built.

——51.6 square kilometers+30% annual growth rate, Pingshan's biopharmaceutical industry is vibrant and has unlimited possibilities

As the host of this event, Pingshan District of Shenzhen has one of the first national biological industry bases in China. The 51.6 square kilometer Pingshan High tech Zone has been included in the core park of Shenzhen High tech Zone. The output value of the biopharmaceutical industry has maintained an average annual growth rate of over 30% in recent years, and more than 80 new biopharmaceutical enterprises are added each year, forming a focus on biopharmaceuticals, high-end medical devices, and biotechnology, with Sanofi Pasteur, Microchip The industrial pattern of mutual promotion and common development among large enterprises represented by Guoyao Zhijun, Xinlitai, New Industry, Libang Precision, and Wanle Pharmaceutical, as well as high-level innovative and innovative enterprises (teams) at home and abroad such as Prikin, Huaxian Pharmaceutical, Wuwei Huasi, and Shengbol, has accelerated the convergence of high-end innovative resources such as Shenzhen Bay Laboratory Pingshan Biopharmaceutical R&D and Transformation Center, Monash University Science and Technology Transformation Research Institute, and Hong Kong Famous Medical Diagnosis and Treatment Center, We already have a good industrial foundation to comprehensively accelerate development and strive to be a leading demonstration.

Looking ahead to the future, Jiang Yuyang, Deputy Director of the Standing Committee of the Shenzhen Municipal People's Congress and Chairman of the Shenzhen Association for Science and Technology, has high hopes for Pingshan District. He pointed out at the summit that "we hope that Pingshan District can seize the important opportunity of the construction of the Guangdong Hong Kong Macao Greater Bay Area and the leading demonstration zone, fully utilize the national level biological industry base as a golden signboard, and build a biopharmaceutical highland with a main position posture to help Shenzhen's biopharmaceutical industry move towards international first-class development.

Based in Shenzhen, deeply cultivating the Greater Bay Area, and facing the world, the Pingshan biopharmaceutical industry will seize the major opportunities of the Guangdong Hong Kong Macao Greater Bay Area and Shenzhen's construction of a leading demonstration zone for socialism with Chinese characteristics, dare to innovate and break through, promote the high-quality and sustainable development of the Pingshan biopharmaceutical industry at a higher starting point, level, and goal, and strive to contribute Pingshan's strength to Shenzhen's construction of a "high-quality development highland"!